Mestag Therapeutics
UK - CambridgeBiotechnology
Focus: Mestag Therapeutics is a Cambridge-based biotech founded in 2016 specializing in fibroblast biology for antibody discovery, currently advancing early-stage cancer immunotherapies into clinical development.
Profile data last refreshed 16h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Total Funding
$45M
Open Jobs
1
Should You Work at Mestag Therapeutics?
AI assessmentBest suited for early-career scientists or clinical professionals seeking ground-floor exposure to a novel platform, but limited stability or breadth for mid-to-senior hires seeking established roles.
Why Work Here
- Recently secured $40M Series A funding (March 2026) to advance lead program MST-0312 into clinic, providing runway and clinical development opportunity.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
MST-0312
Solid MalignanciesClinical Trials (1)
NCT07610941Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies
Phase 1Help build intelligence for Mestag Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.